Analysts See $0.12 EPS for Impax Laboratories, Inc. (IPXL); Last Week Atlas Financial Holdings, Inc. (AFH) Analysts

February 21, 2018 - By Vivian Park

Among 3 analysts covering Atlas Financial Holdings (NASDAQ:AFH), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Atlas Financial Holdings had 5 analyst reports since September 5, 2015 according to SRatingsIntel. On Tuesday, June 13 the stock rating was maintained by Boenning & Scattergood with “Buy”. The company was downgraded on Tuesday, September 8 by TheStreet. The rating was downgraded by TheStreet to “Hold” on Saturday, September 5. Sandler O’Neill maintained it with “Buy” rating and $24.0 target in Wednesday, January 10 report. See Atlas Financial Holdings, Inc. (NASDAQ:AFH) latest ratings:

10/01/2018 Broker: Sandler O’Neill Rating: Buy New Target: $24.0 Maintain

Analysts expect Impax Laboratories, Inc. (NASDAQ:IPXL) to report $0.12 EPS on March, 1 before the open.They anticipate $0.04 EPS change or 25.00% from last quarter’s $0.16 EPS. IPXL’s profit would be $8.62 million giving it 41.04 P/E if the $0.12 EPS is correct. After having $0.23 EPS previously, Impax Laboratories, Inc.’s analysts see -47.83% EPS growth. The stock increased 0.51% or $0.1 during the last trading session, reaching $19.7. About 1.73 million shares traded or 89.92% up from the average. Impax Laboratories, Inc. (NASDAQ:IPXL) has declined 49.01% since February 21, 2017 and is downtrending. It has underperformed by 65.71% the S&P500.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.42 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

Investors sentiment increased to 1.75 in Q3 2017. Its up 0.85, from 0.9 in 2017Q2. It improved, as 14 investors sold Impax Laboratories, Inc. shares while 39 reduced holdings. 39 funds opened positions while 54 raised stakes. 65.84 million shares or 4.79% more from 62.83 million shares in 2017Q2 were reported. Verition Fund Limited Liability Corporation invested in 0.03% or 20,014 shares. 1.99 million were accumulated by Goldman Sachs Gru. Engineers Gate Manager Lp holds 0.14% or 83,366 shares in its portfolio. The New York-based Tiaa Cref Investment Management Limited Company has invested 0% in Impax Laboratories, Inc. (NASDAQ:IPXL). Qs Invsts Ltd Company invested in 0% or 272 shares. Prudential holds 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL) for 124,651 shares. Lsv Asset holds 0% or 10,500 shares in its portfolio. Great West Life Assurance Can invested in 0.01% or 100,872 shares. Employees Retirement Association Of Colorado holds 0% or 12,811 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt System has 0.04% invested in Impax Laboratories, Inc. (NASDAQ:IPXL) for 143,289 shares. Point72 Asset Mngmt Lp accumulated 0.09% or 1.01 million shares. Penn Capital Com invested 0.03% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). Blackrock Inc invested 0.01% in Impax Laboratories, Inc. (NASDAQ:IPXL). Neuberger Berman Limited Liability Co reported 885,238 shares or 0.02% of all its holdings. Barclays Public Ltd Co stated it has 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL).

Among 21 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 6 have Buy rating, 2 Sell and 13 Hold. Therefore 29% are positive. Impax Laboratories Inc. had 47 analyst reports since July 21, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Impax Laboratories, Inc. (NASDAQ:IPXL) rating on Wednesday, August 9. Cantor Fitzgerald has “Buy” rating and $2000 target. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, July 18 report. The firm has “Buy” rating given on Thursday, November 9 by Cantor Fitzgerald. The rating was maintained by UBS on Monday, October 30 with “Sell”. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) earned “Hold” rating by Cowen & Co on Wednesday, August 9. The company was initiated on Wednesday, June 29 by BMO Capital Markets. The rating was initiated by Northland Capital with “Market Perform” on Tuesday, April 19. As per Friday, November 10, the company rating was maintained by Cowen & Co. The firm has “Market Perform” rating given on Tuesday, August 11 by Leerink Swann. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) has “Hold” rating given on Friday, September 15 by Piper Jaffray.

Investors sentiment increased to 1.76 in 2017 Q3. Its up 0.20, from 1.56 in 2017Q2. It is positive, as 6 investors sold Atlas Financial Holdings, Inc. shares while 15 reduced holdings. 11 funds opened positions while 26 raised stakes. 9.03 million shares or 2.06% more from 8.85 million shares in 2017Q2 were reported. Northpointe Capital Limited Liability, Michigan-based fund reported 153,411 shares. Legal And General Grp Inc Public Limited Company invested 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Granite Inv Prtnrs Limited Liability Corporation invested 0.1% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Perritt Cap Mgmt Inc has 419,254 shares. Ancora Lc has 0.01% invested in Atlas Financial Holdings, Inc. (NASDAQ:AFH) for 10,000 shares. Wellington Gp Llp has 0.01% invested in Atlas Financial Holdings, Inc. (NASDAQ:AFH) for 1.19 million shares. Loomis Sayles & Lp holds 0.01% or 226,954 shares in its portfolio. Kennedy Cap Mngmt owns 119,354 shares. Vanguard Grp Inc reported 461,918 shares or 0% of all its holdings. Blackrock reported 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Tower Rech Capital Ltd Liability (Trc) accumulated 0% or 1,291 shares. Howe & Rusling has invested 0% of its portfolio in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Globeflex Lp reported 50,367 shares. Moreover, Ariel Invests Limited has 0.25% invested in Atlas Financial Holdings, Inc. (NASDAQ:AFH) for 1.16M shares. Wcm Inv Management Ca, a California-based fund reported 450,373 shares.

Since August 22, 2017, it had 0 insider purchases, and 17 sales for $702,852 activity. 5,000 shares were sold by KINGSWAY AMERICA INC, worth $85,775 on Monday, September 11. Giles Bruce Wayne sold $12,522 worth of stock or 657 shares. On Thursday, December 14 DiMaggio Leslie sold $12,522 worth of Atlas Financial Holdings, Inc. (NASDAQ:AFH) or 657 shares. 1,055 Atlas Financial Holdings, Inc. (NASDAQ:AFH) shares with value of $20,108 were sold by Wollney Scott D. On Thursday, December 14 Romano Paul Anthony JR sold $14,924 worth of Atlas Financial Holdings, Inc. (NASDAQ:AFH) or 783 shares. Another trade for 657 shares valued at $12,522 was made by Shugrue Joseph Raymond on Thursday, December 14.

The stock decreased 1.63% or $0.3 during the last trading session, reaching $18.15. About 14,478 shares traded. Atlas Financial Holdings, Inc. (NASDAQ:AFH) has declined 15.27% since February 21, 2017 and is downtrending. It has underperformed by 31.97% the S&P500.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>